Balyasny Asset Management’s Rhythm Pharmaceuticals RYTM Stock Holding History

Balyasny Asset Management’s Portfolio RYTM Stock Details RYTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.61M	Sell	52,967 -19,315	-27%	-$1.88M	0.01%	1394
2025 Q4	$7.74M	Sell	72,282 -277,726	-79%	-$29.5M	0.01%	1164
2025 Q3	$35.3M	Buy	350,008 +295,920	+547%	+$27.5M	0.04%	485
2025 Q2	$3.42M	Sell	54,088 -301,624	-85%	-$18.5M	0.01%	1479
2025 Q1	$18.8M	Buy	355,712 +217,349	+157%	+$12.1M	0.03%	623
2024 Q4	$7.75M	Buy	+138,363	New	+$7.64M	0.01%	1081
2023 Q2	–	Sell	-16,313	Closed	-$291K	–	2729
2023 Q1	$291K	Buy	16,313 +15,547	+2,030%	+$390K	﹤0.01%	2122
2022 Q4	$22.3K	Buy	+766	New	+$19.7K	﹤0.01%	2471

Other funds holding RYTM

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Balyasny Asset Management's RYTM Position: Q1 2026 in Review

Balyasny Asset Management reduced its Rhythm Pharmaceuticals (RYTM) stake by 27% in Q1 2026, selling an estimated $1.88M and leaving 52,967 shares worth $4.61M. The position accounts for 0.01% of the portfolio, ranked #1394.

Balyasny Asset Management first reported a position in RYTM in Q4 2022 and has held it in 8 quarters since. The position peaked at $35.3M in Q3 2025. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.

Balyasny Asset Management held 52,967 shares of Rhythm Pharmaceuticals worth $4.61M as of Q1 2026.
Balyasny Asset Management sold 19,315 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $1.88M.
Rhythm Pharmaceuticals made up 0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #1394 holding.
Balyasny Asset Management first reported a position in Rhythm Pharmaceuticals in Q4 2022 and has held it in 8 quarters since.
Balyasny Asset Management's Rhythm Pharmaceuticals position peaked at $35.3M in Q3 2025.
285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.